Bloomage Biotech(SH:688363) Shen Zhen Shang Bao·2025-09-11 18:05Group 1 - The core viewpoint of the articles highlights Huaxi Biological's strategic shift towards innovative pharmaceuticals amid declining performance in its collagen protein brands [1][2] - Huaxi Biological's investment in Saint Nor Pharmaceutical through its subsidiary Bloomage Biotechnology amounts to HKD 138 million, acquiring approximately 9.44% of the company [1] - The company has faced significant challenges, with a 29.74% year-on-year decline in functional skincare product revenue in the first half of 2024, contributing to a 19.57% drop in overall revenue in the first half of 2025 [2] Group 2 - Multiple social media platforms reported the closure of Huaxi Biological's collagen protein brand "Runxiquan," with its Tmall flagship store and other online shops ceasing operations [1] - The brand had set a revenue target of CNY 1 billion from 2020 to 2024 but only achieved CNY 300 million, leading to significant downsizing of related teams from over 100 to around 10 [1] - The strategic partnership with Saint Nor Pharmaceutical is seen as a crucial move for Huaxi Biological to enhance its clinical and commercialization processes in the medical aesthetics pipeline [2]